Media
[News] Hua Medicine Announces Multiple Personnel Appointments
March 30, 2023, Shanghai, China
Hua Medicine (the "Company", stock code: 2552.HK) today announces that Mr. George Chien Cheng Lin has been appointed Chief Strategy Officer of Hua Medicine. Mr. Lin will assume responsibility for corporate strategy for the Company, in addition to his current responsibilities for business development, capital markets and investor relations. Mr. Lin will continue to serve as Executive Director of the Company. Following this appointment, Mr. Lin will no longer hold the title of Chief Financial Officer of the Company.
In addition, Mrs. Hou Ping (侯萍) has been promoted to VP of Finance and will continue to supervise and be responsible for the accounting, internal control, financial operation and tax regulation functions of the Company. Mrs. Hou Ping joined Hua Medicine in 2017 as a consultant for internal control in finance department and was appointed as Director of Internal Audit in 2019. She served as Director of Finance in 2021 overseeing the financial operations.
Mrs. Hairong Wang (王海蓉) has been promoted to VP of Corporate Human Resources and will continue to supervise and be responsible for the human relations functions of the Company. Mrs. Wang has over 25 years of experience in the corporate management, human resources, marketing and commercial operations fields.
We have also appointed Mr. Gary Yu (余剛）as VP of Regulatory Affairs and Mrs. Michelle Zhu (朱燕敏）as VP of Industry Policy and Regulations. Mr. Yu joined Hua Medicine in 2013 as Director of Regulatory Affairs and was responsible for dorzagliatin regulatory entry and approval in China. Prior to joining Hua Medicine, Mr. Yu served as vice president for a China biotechnology company focused on developing GLP-1 drug candidates for the treatment of diabetes. Mrs. Zhu joined Hua Medicine as a Sr. Director of Industrial Policy and Regulations and has led the Hua Medicine team to advance MAH policy and ensure dorzagliatin regulatory approval and commercialization. She has over 25 years of industry experience and was a director of government affairs at Boehringer Ingelheim and Abbott in China.
Dr. Li Chen, Founder and CEO of Hua Medicine, said, "As we continue to accelerate our commercialization of HuaTangNing (華堂寧?), we have taken this opportunity to establish our stable corporate, administrative and operations roles and organization chart. While the Company has experienced incredible growth and transitions from a pure innovative-focused R&D company into a commercialization company tasked with advancing global diabetes care, we are very proud that our appointed officers have had a lengthy tenure with Hua Medicine already in building the company into the global first-in-class biopharmaceutical company, and we expect that longevity of relationship to continue while we continue to focus on our mission from day one of providing a better treatment for diabetes patients globally."
About Hua Medicine
Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global high-caliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care. As Hua Medicine's cornerstone product, HuaTangNing (華堂寧?) targets the glucose sensor, glucokinase, restores glucose sensitivity in T2D patients and stabilizes the imbalance of blood glucose levels in patients. HuaTangNing (華堂寧?) was approved by the National Medical Products Administration (NMPA) of China on September 30, 2022. It can be used alone or in combination with metformin hydrochloride-tolerated T2D patients. For those patients with chronic kidney disease (CKD) and Type 2 diabetes (i.e., diabetes kidney disease), no dose adjustment is required. Hua Medicine has partnered with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing (華堂寧?) in China, benefiting diabetic patients and their families. HuaTangNing (華堂寧?) has also demonstrated its potential of achieving diabetes remission in clinical studies to help millions of diabetic patients around the world.
For more information
Hua Medicine
Website: yi92.cn
Investors
Email: ir@huamedicine.com
Media
Email: pr@huamedicine.com
滬ICP備14036654號(hào)-1
滬公網(wǎng)安備 31011502013809號(hào) Privacy Statement Terms of Use
